4 citations
,
March 2020 in “Cutaneous and ocular toxicology” In this double-blind, randomized controlled study, researchers found that Wen by Chaz Dean Sweet Almond Mint Cleansing Conditioner was similarly tolerated compared to three other hair cleansing conditioners and was significantly better tolerated than salicylic acid shampoo or baby shampoo in terms of skin reactions.
2 citations
,
December 2023 in “Journal of clinical immunology” This study describes the positive effects of the JAK inhibitor ruxolitinib in treating autoimmune manifestations in three patients with autoimmune polyendocrine syndrome type-1 over a period of at least 30 months, with excellent tolerance and no adverse events observed.
September 2021 in “Research Square (Research Square)” This study reports that despite rescuing neurulation and skin barrier defects, Grhl3 gene overexpression in mice leads to hearing impairment, hair loss, and other developmental abnormalities, highlighting low tolerance for Grhl3 dysregulation.
104 citations
,
August 2008 in “Clinics in Dermatology” This review discusses current treatment challenges and strategies for managing psoriasis in the scalp, nails, and intertriginous areas, emphasizing the need for effective and well-tolerated long-term options, but reports no new clinical results.
60 citations
,
December 2015 in “Lasers in Medical Science” This review concluded that FDA-cleared low-level laser therapy devices are safe and effective for patients with male and female pattern hair loss who do not respond to or tolerate standard treatments.
49 citations
,
November 1992 in “Archives of dermatology” This article discusses the emotional and psychological impact of severe alopecia areata on patients, emphasizing feelings of loss, vulnerability, and self-identity changes, and reports no new results.
46 citations
,
January 2008 in “Climacteric” Randomized trials reported that testosterone therapy improved sexual function in postmenopausal women with hypoactive sexual desire disorder, particularly those who had undergone oophorectomy, with reversible and well-tolerated side effects.
34 citations
,
February 2018 in “Drug Design Development and Therapy” This source reports that bimatoprost, a medication approved for eyelash growth, has shown efficacy in treating eyebrow hypotrichosis, suggesting it as a noninvasive, effective, and well-tolerated option for enhancing eyebrow hair.
1 citations
,
June 2023 in “Advances in therapy” In a real-world registry study, ripretinib showed effectiveness with a median progression-free survival of 7.70 months and a tolerable safety profile in Chinese patients using it as a fourth-line treatment for advanced GIST, particularly benefiting those with non-gastric tumors.
July 2026 in “Clinical Cosmetic and Investigational Dermatology” In this cross-sectional study of healthy urban women in Shanghai, poor sleep quality and elevated perceived stress were linked to various self-reported dermatological issues and clinical signs, reinforcing the potential relevance of psychological factors in skin health.
January 2026 in “International Journal of Dermatology Venereology and Leprosy Sciences” In this randomized study, intradermal injections of dutasteride effectively improved androgenetic alopecia in 15 male patients, showing significant clinical improvement within one month and being well-tolerated without notable side effects, though the improvement was negatively correlated with longer disease duration.
December 2025 in “International Journal of Research in Dermatology” This clinical study in healthy Indian adults found that a four-month application of an Ayurvedic leave-on treatment significantly increased natural black hair density, reduced grey hair count, and was well-tolerated without adverse effects, suggesting its efficacy and safety for treating premature hair greying.
September 2024 in “Drugs & Therapy Perspectives” In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.
9 citations
,
October 2020 in “Journal of The American Academy of Dermatology” This letter discusses the limited adaptation of low dose oral minoxidil for androgenetic alopecia in North America and reports no new clinical results; the authors suggest safety concerns or unclear dosing may be factors.
1 citations
,
January 2020 in “IRIS UNIMORE (University of Modena and Reggio Emilia)” This study found that Aminexil clinical 5 significantly reduced hair loss in men and women with mild alopecia and was well tolerated with high subject satisfaction.
April 2026 in “Frontiers in Medicine” In this study, young female medical students at King Saud University reported a higher prevalence of physician-diagnosed PCOS compared to similar Western populations, and hirsutism was notably associated with the condition, highlighting the need for early screening and health education.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
118 citations
,
January 2013 in “Biomaterials” This study characterized keratin-based biomaterials that self-assemble into hydrogels, demonstrating their potential to achieve hemostasis in a lethal liver injury model through specific biomaterial-receptor interactions.
2 citations
,
May 2016 in “Journal of Clinical Oncology” This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.
February 2025 in “Advances in Therapy” The topical finasteride spray was safe and well-tolerated with stable effects.
May 2019 in “Journal of clinical oncology” This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.
9 citations
,
June 2025 in “Journal of Clinical Medicine” The authors concluded that while PRP is a promising and well-tolerated treatment for early to moderate knee osteoarthritis, standardizing preparation protocols, patient selection, and outcome reporting is crucial to enhance comparability and inform clinical practice.
8 citations
,
June 2022 in “Frontiers in Medicine” This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.
5 citations
,
February 2025 in “Pediatric Dermatology” In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.
2 citations
,
December 2021 in “Aesthetic surgery journal” This study found that a silicone gel dressing was well-tolerated and may accelerate early wound healing compared to Bacitracin in patients undergoing follicular unit extraction, but both achieved similar outcomes by day 7.
1 citations
,
May 2017 in “Journal of Clinical Oncology” This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.
July 2026 in “Applied Sciences” This review suggests that 308 nm excimer therapy may offer a well-tolerated non-pharmacologic option for alopecia areata, with more limited evidence for its effectiveness in lichen planopilaris and frontal fibrosing alopecia.
August 2025 in “Skin Appendage Disorders” This review highlights that while low-dose oral minoxidil appears well-tolerated in cancer patients post-chemotherapy, its use during active chemotherapy has shown potential benefits but remains under investigation, with preclinical studies suggesting a protective effect against chemotherapy-induced alopecia.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” This review discusses common cutaneous reactions to targeted cancer drugs such as tyrosine kinase inhibitors and reports no new clinical results.
16 citations
,
August 2021 in “Frontiers in Pharmacology” This study found that a nano-preparation of quercetin, using a self-nanoemulsifying drug delivery system, was more effective than standard quercetin in reducing cardiac complications and tissue damage in rats with metabolic syndrome, although both formulations similarly reduced oxidative and inflammatory markers.